
November 2, 2020

Listing Department
BSE LIMITED
P J Towers, Dalal Street, Fort,
Mumbai – 400 001

Code: 532 321

Listing Department
NATIONAL STOCK EXCHANGE OF INDIA LIMITED
Exchange Plaza, Bandra Kurla Complex,
Bandra (E),
Mumbai – 400 051

Code: CADILAHC

Re.: Press Release

Dear Sir/Madam,

Please find enclosed a copy of press release dated November 2, 2020 titled “**Zydus to present PBC and NASH clinical trial data of Saroglitazar Mg at the AASLD's The Liver Meeting Digital Experience™ 2020**”.

The contents of the press release give full details.

Please bring the aforesaid news to the notice of the members of the exchange and the investors' at large.

Thanking you,

Yours faithfully,
For, **CADILA HEALTHCARE LIMITED**


DHAVAL N. SONI
COMPANY SECRETARY

Encl.: As above

Zydus to present PBC and NASH clinical trial data of Saroglitazar Mg at the AASLD's The Liver Meeting Digital Experience™ 2020

Ahmedabad, India, November 2, 2020

Zydus, a leading discovery based, global pharmaceutical company today announced that a Late-Breaker Oral Presentation and two Poster Presentations on Saroglitazar Mg has been accepted for presentation at The Liver Meeting® 2020, the Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), which is taking place virtually from November 13-16, 2020.

Saroglitazar Mg is in various stages of clinical trials to evaluate the safety, tolerability, and efficacy in patients with Primary Biliary Cholangitis (PBC) and Non Alcoholic Steato Hepatitis (NASH).

Speaking on the development, Pankaj R. Patel, Chairman, Cadila Healthcare Ltd., said, “We look forward to present the new data on Saroglitazar Mg at The Liver Meeting Digital Experience™, the Annual Meeting of the American Association for the Study of Liver Diseases (AASLD). Zydus is committed to developing novel therapies for patients living with liver diseases like PBC and NASH”.

Abstract Title: “RESULTS OF PHASE 2, PROSPECTIVE, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE SAFETY, TOLERABILITY AND EFFICACY OF SAROGLITAZAR MAGNESIUM IN PATIENTS WITH PRIMARY BILIARY CHOLANGITIS (EPICS)”

Publication Number : LO12
Session Title : Late-breaking Oral Session 2
Presentation Type : Oral presentation
Session Date and Time : Monday, November 16, 2020, 2:00 PM

Abstract Title: “SAROGLITAZAR, A DUAL PPAR α/γ AGONIST, RESOLVED STEATOHEPATITIS IN A RANDOMIZED DOUBLE BLINDED PLACEBO CONTROLLED PHASE 2 PROOF OF CONCEPT PILOT TRIAL”

Publication Number : 1695
Session Title : NAFLD and NASH: Therapeutics - Pharmacologic and Other
Presentation Type : Poster Presentation

Abstract Title: “SAROGLITAZAR ATTENUATES PRIMARY SCLEROSING CHOLANGITIS IN Mdr2^{-/-} MICE MODEL: A COMPARISON WITH OBETICHOLIC ACID”

Publication Number : 1270

Session title : Human Cholestatic and Autoimmune Liver Diseases: PBC/PSC and Other Cholestatic Diseases; Autoimmune Liver Disease

Presentation Type : Poster Presentation

About Primary Biliary Cholangitis (PBC)

PBC is a liver disease, caused due to progressive destruction of the bile ducts in the liver which leads to reduction of bile flow – a condition referred to as cholestasis. With an increasing number of people being affected by PBC which can lead to progressive cholestasis and even turn fatal, there is a pressing need to develop therapies which help to achieve an adequate reduction in Alkaline Phosphatase (ALP) or bilirubin and bring in better tolerance and efficacy.

About NASH

NASH is a progressive disease of the liver, which starts with fat accumulation in the liver known as Non-Alcoholic Fatty Liver Disease (NAFLD). This condition could progress to cirrhosis and liver failure. Liver transplantation is the only option for managing advanced cirrhosis with liver failure.

About Zydus

Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies, including small molecule drugs, biologic therapeutics and vaccines. The group employs nearly 25,000 people worldwide, including 1,400 scientists engaged in R & D, and is dedicated to creating healthier communities globally. www.zyduscadila.com
